POLIDOCANOL INJECTION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global Polidocanol Injection Market Size and Forecast – 2025-2032

The Global Polidocanol Injection Market is estimated to be valued at USD 92.7 million in 2025 and is expected to reach USD 154.8 million by 2032, exhibiting a compound annual growth rate (CAGR) of 7.6% from 2025 to 2032. The market is driven by the increasing prevalence of varicose veins and the rising demand for minimally invasive treatment options.

Key Takeaways of the Global Polidocanol Injection Market:

• Varicose veins treatment holds the largest share in the global polidocanol injection market by application, accounting for an estimated 35.6% in 2025, driven by its high prevalence and increasing preference for minimally invasive surgeries.
• By formulation, liquid formulation is expected to lead the market with a 52.1% share in 2025, owing to its established safety, ease of use, and treatment versatility.
• The branded segment dominates by type, capturing an estimated 53.4% of the market share in 2025, supported by strong clinical trust, proven efficacy, and regulatory approvals.
• North America is expected to lead the market, holding a share of 38.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 30.3% in 2025.

Market Overview:

The trend in the polidocanol injection market is towards the development of advanced formulations and delivery systems that enhance the efficacy and safety of the treatment. Additionally, there is a growing focus on expanding the application of polidocanol injections beyond varicose veins, such as in the treatment of hemorrhoids and esophageal varices, where they are increasingly being considered as a minimally invasive alternative within the broader category of hemorrhoid treatment devices.

Currents Events and their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Analysis

To learn more about this report, Request sample copy

Polidocanol Injection Market Insights, By Application - Varicose Veins Treatment Dominates Due to High Prevalence and Minimally Invasive Demand

In terms of application, varicose veins treatment is expected to contribute the highest share of the market with 35.6% in 2025 owing to several key factors. Varicose veins are a common chronic venous disorder affecting a significant portion of the global population. The increasing prevalence of varicose veins, coupled with the rising awareness about the availability of minimally invasive treatment options, has fueled the demand for polidocanol injections in this segment.

Polidocanol injections offer a safe, effective, and non-surgical solution for the treatment of varicose veins. The procedure, known as sclerotherapy, involves injecting polidocanol directly into the affected veins, causing them to collapse and eventually disappear. This minimally invasive approach has gained popularity due to its high success rates, minimal downtime, and cosmetic benefits.

For instance, in February 2025, Theraclion, a France-based innovator in non-invasive high-intensity focused ultrasound (HIFU) systems, started clinical trials for its new SONOVEIN ‘SpeedPulse’ feature in Europe. The upgrade aims to significantly reduce treatment time for varicose veins using advanced acoustics and ultrasound pulsing. Early results show promising speed improvements, with commercialization planned post regulatory approval.

Polidocanol Injection Market Insights, By Formulation - Liquid Formulation Dominates Owing to Proven Safety and Versatility

In terms of formulation, liquid formulation is expected to contribute the highest share of the global polidocanol injection market with a share of 52.1% in 2025. Several factors have contributed to the dominance of liquid formulations in this market.

Liquid polidocanol injections have been widely used in sclerotherapy procedures for decades, establishing a strong track record of safety and efficacy. Healthcare professionals are well-versed in the preparation, dosing, and administration of liquid formulations, making them a familiar and trusted choice.

One of the key advantages of liquid formulations is their versatility in treating various vein sizes and types. Liquid polidocanol can be easily adjusted in terms of concentration and volume to address specific patient needs, allowing for customized treatment plans. This flexibility has made liquid formulations a go-to choice for healthcare providers.

Polidocanol Injection Market Insights, By Type - Branded Segment Dominates Due to Clinical Trust and Regulatory Backing

The branded segment is expected to hold the dominant share in the global polidocanol injection market with a share of 53.4% in 2025, driven by strong clinical trust, proven efficacy, and regulatory approvals. Products like Varithena by Boston Scientific and Asclera by Methapharm have established brand recognition and are widely used in developed healthcare systems due to their consistent quality and favorable patient outcomes.

Physicians prefer branded formulations for their safety profiles, standardized dosing, and strong post-marketing surveillance, making them the preferred choice in hospital and specialty clinic settings. As a result, the branded segment leads the market both in terms of revenue and adoption in high-value procedures.

Regional Insights:

To learn more about this report, Request sample copy

North America Polidocanol Injection Market Analysis and Trends

In North America, the dominance in the global polidocanol injection market with a share of 38.3% in 2025 can be attributed to several factors. The region boasts a well-established healthcare infrastructure, coupled with a high adoption rate of advanced medical treatments. The presence of major pharmaceutical companies and their significant investments in research and development activities have further fueled the growth of the market. Moreover, favorable reimbursement policies and increasing awareness about minimally invasive procedures have contributed to the widespread acceptance of polidocanol injections in the region.

For instance, according to the National Library of Medicine, in August 2022, Varicose Veins (VVs) are a widespread venous disorder impacting people across all age groups, including adolescents, adults, and the elderly. In the U.S. alone, approximately 33 million adults are affected, with a significantly higher prevalence in women (22 million) compared to men (11 million). The condition is most frequently observed in individuals between the ages of 40 and 80. This high disease burden, combined with increasing awareness, a growing preference for minimally invasive treatments like sclerotherapy, and the availability of advanced products such as branded polidocanol injections, is expected to drive the growth of the North America polidocanol injection market.

Asia Pacific Polidocanol Injection Market Analysis and Trends

Meanwhile, the Asia Pacific region exhibits the fastest growth in the global polidocanol injection market with an estimated share of 30.3% in 2025. The rapid economic development, rising disposable incomes, and increasing healthcare expenditure in countries like China and India have created a conducive environment for market expansion. Furthermore, the growing medical tourism industry and the establishment of advanced healthcare facilities in the region have attracted a significant number of patients seeking cost-effective treatment options. Government initiatives to improve healthcare access and awareness campaigns about minimally invasive procedures have also contributed to the market's growth.

For example, Troikaa Pharmaceuticals specializes in a variety of pharmaceutical products, including polidocanol for sclerotherapy. They are dedicated to delivering high-quality treatments that support healthcare providers in managing vascular conditions.

Global Polidocanol Injection Market Outlook for Key Countries:

U.S. Polidocanol Injection Market Trends

The U.S. market for polidocanol injections is characterized by a high demand for minimally invasive cosmetic procedures. The country's advanced healthcare infrastructure, coupled with a large population of health-conscious individuals, has fueled the adoption of polidocanol injections. The market growth is further supported by favorable reimbursement policies and a strong emphasis on patient safety and satisfaction.

For example, LGM Pharma is a U.S.-based contract development and manufacturing organization (CDMO) and API supplier. It provides bulk polidocanol API to pharmaceutical companies for formulation and clinical manufacturing in the U.S. and globally.

India Polidocanol Injection Market Trends

The India polidocanol injection market is witnessing steady growth, driven by increasing awareness about minimally invasive treatments for varicose and spider veins. Rising incidences of chronic venous disorders, particularly among middle-aged and elderly populations, have fueled the demand for effective and affordable sclerotherapy options.

For example, Indian pharmaceutical companies such as Healthizalife, a healthcare-focused Indian pharmaceutical firm actively involved as a supplier, manufacturer, and exporter of Polidocanol Injection, ensures that its range of pharmaceutical products is thoroughly tested by experts to verify its effectiveness across multiple quality parameters.

China Polidocanol Injection Market Trends

China continues to lead the Asia Pacific region in the global polidocanol injection market. The country's vast population, coupled with rising disposable incomes and increasing healthcare expenditure, has created a significant demand for minimally invasive treatments. The government's initiatives to improve healthcare infrastructure and promote medical innovation have further accelerated market growth. Companies, such as OCEAN PHARMACEUTICAL, is known for its diverse range of pharmaceutical products, including polidocanol injections. It aims to enhance patient care by providing reliable and effective treatments for sclerotherapy procedures.

Japan Polidocanol Injection Market Trends

Japan's market for polidocanol injections is characterized by a high emphasis on quality and safety. The country's stringent regulatory environment and advanced healthcare technology have ensured the availability of high-quality polidocanol injection products. The market growth is further supported by an aging population and increasing demand for minimally invasive cosmetic procedures.

End User Feedback and Unmet Needs – Global Polidocanol Injection Market

• End users of polidocanol injections, primarily dermatologists, vascular surgeons, and aesthetic practitioners, report a high level of satisfaction with the product’s efficacy in treating varicose veins and sclerotherapy for vascular malformations. A recurring positive observation is its minimal invasiveness and favorable safety profile compared to traditional surgical interventions. For instance, clinicians in outpatient dermatology centers have cited rapid patient recovery times and reduced incidence of post-procedure complications, such as thrombophlebitis or hyperpigmentation, as key advantages. Moreover, its compatibility with ultrasound-guided procedures has been positively acknowledged by vascular surgeons who utilize foam formulations in larger vein treatments. This has made polidocanol a preferred choice in both cosmetic and therapeutic practices where patient comfort and procedural efficiency are critical.
• Despite these benefits, several unmet needs and challenges remain. One common concern among practitioners in developing markets is the high cost and inconsistent availability of branded formulations, which limits access for cost-sensitive healthcare systems and patients. Additionally, users have expressed the need for expanded product customization—particularly in foam concentration, packaging sizes, and delivery systems—to cater to varying clinical settings and patient needs. Government hospitals and public health bodies in emerging economies also report a lack of training and educational support, impacting the safe and effective administration of the drug. Addressing these gaps by offering flexible pricing models, localized production, and comprehensive clinician training programs could enhance adoption rates, expand access in underserved markets, and position manufacturers for long-term growth and differentiation.

Market Players, Key Developments, and Competitive Intelligence:

To learn more about this report, Request sample copy

Company Insights:

• Samarth Life Sciences Pvt Ltd is an Indian pharmaceutical company recognized for its specialization in injectables, critical care, and specialty medicines. With a strong presence in both domestic and export markets, Samarth operates WHO-GMP certified manufacturing facilities and maintains a reputation for innovation-driven production. In the Polidocanol Injection segment, Samarth offers a product marketed as Asklerol, available in a 3% concentration in 2 mL ampoules. This injection is primarily used in sclerotherapy procedures for treating spider veins, uncomplicated reticular veins, and small varicose veins. The formulation is widely accepted in clinical practices for its anesthetic effect and consistent vein-irritating action, which supports effective sclerosis of damaged veins.
• Aetos Pharma Pvt Ltd is an emerging pharmaceutical manufacturer based in India, focusing on a wide range of generic formulations including injectables, tablets, and APIs. The company has WHO-GMP, ISO, and CE certifications, and it exports to numerous regulated and semi-regulated markets across the globe. In the Polidocanol Injection market, Aetos manufactures a 3% solution in 2 mL vials intended for use in the treatment of spider veins, reticular veins, and larger incompetent saphenous veins. The product is used by dermatologists and vascular surgeons for its safety, efficacy, and affordability. Aetos maintains high quality standards while ensuring competitive pricing for hospitals and clinics.
• SAINTROY Lifescience, headquartered in, Gujarat, India  is a leading Indian exporter and manufacturer of pharmaceuticals, specializing in injectable and oral formulations. The company supplies to clients across Asia, Africa, and Latin America and offers contract manufacturing and private-label services. SAINTROY produces Polidocanol Injection at a strength of 10 mg/mL in sterile liquid form. The product is distributed in bulk quantities or as private-label formulations resembling global brands like Asclera and Aethoxysklerol. It is primarily used for cosmetic and medical vein sclerotherapy. SAINTROY is known for offering flexible order sizes and cost-effective solutions to global pharma distributors and clinics.

Top Strategies Followed by Global Polidocanol Injection Market Players

• Established players in the global polidocanol injection market are focusing on extensive research and development to innovate high-performance products. These companies invest heavily in R&D to enhance the efficacy, safety, and quality of their polidocanol injection offerings. Additionally, they engage in strategic partnerships with major industry players or original equipment manufacturers (OEMs) to solidify their market presence. These alliances help them leverage shared resources, expertise, and distribution networks to expand their reach and strengthen their position in the market.
  • For example, Boston Scientific Corporation is a global medical device company specializing in minimally invasive treatments. It markets Varithena, an U.S. FDA-approved 1% polidocanol injectable foam used for treating incompetent great saphenous veins, widely adopted in vein clinics across the globe.

• Mid-level players operate at a regional or multi-country level and are often focused on producing generic formulations to cater to growing demand in emerging markets. While they may not have the same R&D intensity or regulatory leverage as global leaders, they bridge the gap between accessibility and affordability. Their competitive advantage lies in cost-efficiency, agility in responding to regional healthcare needs, and adaptability to local regulatory frameworks.
  • For example, SGPharma produces POLICAN, a polidocanol-based sclerosant licensed for varicose vein treatment. The injection incorporates mild anesthetic effects, making sclerotherapy relatively painless when used with compression bandages

• Small-scale players in the global polidocanol injection market are adopting niche specialization strategies to differentiate themselves from larger competitors. They target specific market segments with unique features or innovative products tailored to meet the particular needs of those niches. Moreover, these players are leveraging cutting-edge technologies to remain competitive in the market.
  • For example, Labdhi Pharmaceuticals is known for its diverse range of pharmaceutical offerings, including polidocanol injections. It emphasizes quality manufacturing practices to ensure its products are safe and effective for sclerotherapy applications.

Research Results and Insights

• In February 2021, a case report published by the National Library of Medicine highlighted a successful non-surgical treatment for multiple large gastrointestinal (GI) hemangiomas using polidocanol sclerotherapy. A 46-year-old female patient was treated with endoscopic multipoint injections of polidocanol, resulting in the complete regression of esophageal and gastric hemangiomas without complications. This method presents a minimally invasive alternative to traditional surgery for vascular lesions in the digestive tract, offering faster recovery and reduced trauma.
• On July 4, 2022, According to the article published in the journal Frontiers in Pediatrics. The study was a meta-analysis of 11 clinical studies involving 287 patients that evaluated the effectiveness of polidocanol in treating venous malformations (VMs). It found that approximately 89% of patients experienced a reduction in lesion size by 50% or more, with minimal statistical heterogeneity across the included studies. Polidocanol demonstrated effectiveness across different anatomical sites and age groups. Importantly, no serious complications were reported, and the authors concluded that polidocanol had proven to be both a safe and effective sclerosing agent for the treatment of VMs.

Market Report Scope

Polidocanol Injection Market Dynamics

To learn more about this report, Request sample copy

Polidocanol Injection Market Driver - Increasing Prevalence of Varicose Veins

The rising prevalence of varicose veins worldwide is a significant driver for the growth of the global polidocanol injection market. Varicose veins are a common condition characterized by enlarged, twisted, and painful veins, typically occurring in the legs. Factors such as aging, obesity, sedentary lifestyles, and genetics contribute to the development of varicose veins.

Polidocanol injections, also known as sclerotherapy, have emerged as a preferred minimally invasive treatment for varicose veins due to their efficacy, safety, and minimal downtime. The growing awareness among patients and healthcare providers about the benefits of polidocanol injections in managing varicose veins is further fueling the market growth.

For Instance, According to National Library of Medicine report, In December 2023, Varicose veins are among the most common vascular disorders worldwide, affecting 10–30% of people. While usually not painful at first, their appearance is often what leads people to seek medical attention.

Polidocanol Injection Market Opportunity - Growing Awareness of Cosmetic Procedures

The increasing awareness of cosmetic procedures presents a significant opportunity for the global polidocanol injection market. In recent years, there has been a growing trend towards minimally invasive aesthetic treatments, with more individuals seeking solutions to enhance their appearance and boost their self-confidence. Polidocanol injections, particularly for the treatment of spider veins and other cosmetic vascular concerns, have gained popularity due to their effectiveness and relatively short recovery time compared to more invasive surgical options.

As consumers become more informed about the available cosmetic treatments and their potential benefits, the demand for polidocanol injections is expected to rise. This growing awareness is fueled by various factors, including social media influence, celebrity endorsements, and increasing disposable income in many regions worldwide.

For Instance, According to data by National Library of Medicine report, in October 2021, Polidocanol sclerotherapy is a safe and effective treatment for venous malformations, as shown by a retrospective study of 84 patients who underwent the procedure between 2020 and 2022. The treatment led to significant reductions in pain, swelling, functional limitation, and cosmetic concerns, with most malformations located in the extremities. 

Analyst Opinion (Expert Opinion)

• The global polidocanol injection market is witnessing strong growth driven by a confluence of factors including the increasing prevalence of chronic venous disorders, rising demand for minimally invasive treatments, and favorable regulatory support across developed and emerging markets. Technological advancements in foam-based formulations have enhanced treatment efficacy and patient compliance, particularly in varicose vein and hemorrhoid management. The market is also benefitting from the growing geriatric population and improved insurance coverage for outpatient sclerotherapy procedures. However, challenges such as fluctuating raw material costs, uneven regulatory harmonization, and limited awareness in lower-income regions still hinder optimal penetration. Emerging opportunities lie in expanding therapeutic applications beyond vascular use and increasing market presence in Asia Pacific and Latin America through strategic partnerships and localization.
• Notably, international events such as the International Vein Congress (U.S.), European Venous Forum (Europe), and VEITHsymposium have played pivotal roles in showcasing advancements in sclerosing therapies, including polidocanol innovations. These platforms have fostered clinical consensus, published outcome-based studies, and promoted global standardization of treatment protocols. In terms of impactful initiatives, companies like BTG International (Boston Scientific) have expanded access to polidocanol-based therapies through licensing deals, while governments in China and Brazil have introduced pilot programs to integrate sclerotherapy into public vascular clinics. These developments are expected to reshape market access models and support long-term adoption across diversified care settings.

Market Segmentation

•  Application Insights (Revenue, USD Mn, 2020 - 2032)
• • Varicose Veins Treatment
  • Hemorrhoid Management
  • Sclerotherapy
  • Vascular Malformations
  • Others Procedures
•  Formulation Insights (Revenue, USD Mn, 2020 - 2032)
• • Liquid Formulation
  • Foam Formulation
•  Type Insights (Revenue, USD Mn, 2020 - 2032)
• • Branded
  • Generic
•  Package Form Insights (Revenue, USD Mn, 2020 - 2032)
• • Vials (single dose)
  • Pre‑filled syringes
  • Ampoules
•  Dosage Strength Insights (Revenue, USD Mn, 2020 - 2032)
• • 10 mg per unit
  • 20 mg per unit
  • 60 mg per unit
  • 5 % solution
  • 1 % solution
  • 3 % solution
•  Age Group Insights (Revenue, USD Mn, 2020 - 2032)
• • Pediatrics
  • Adult
  • Geriatric
•  Gender Insights (Revenue, USD Mn, 2020 - 2032)
• • Male
  • Female
•  Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
• • Online Sales
  • Offline Sales
•  End User Insights (Revenue, USD Mn, 2020 - 2032)
• • Hospitals
  • Ambulatory Surgical Centers
  • Dermatology Clinics
  • Academic & Research Institutes
  • Others
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Boston Scientific Corporation
  • Aetos Pharma Private Limited
  • OCEAN PHARMACEUTICAL
  • SGPharma Pvt. Ltd.
  • SAINTROY LIFESCIENCE
  • healthizalife
  • Samarth life sciences pvt ltd
  • LGM Pharma
  • Methapharm Inc.
  • Troikaa Pharmaceuticals Ltd.
  • Akshar Pharma
  • Labdhi Pharmaceuticals

Sources

Primary Research Interviews:

• Clinical Researchers and Dermatologists
• Hospital Procurement Managers
• Regulatory Affairs Specialists
• Pharmacovigilance Officers
• Heads of Clinical Trials and Medical Affairs
• Pharmaceutical Distributors and Wholesalers

Databases:

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Pharmaceuticals and Medical Devices Agency (PMDA), Japan
• Central Drugs Standard Control Organization (CDSCO), India
• World Health Organization (WHO)

Magazines:

• PharmaTimes
• Pharmaceutical Technology
• The Pharma Letter
• Drug Development & Delivery
• Scrip Intelligence

Journals:

• Journal of Clinical and Aesthetic Dermatology
• International Journal of Dermatology
• Pharmaceutical Research
• European Journal of Pharmaceutical Sciences
• International Journal of Drug Delivery
• Journal of Vascular Surgery

Newspapers:

• Reuters Health
• The New York Times – Health Section
• BBC Health
• MedPage Today

Associations:

• International Union of Phlebology (UIP)
• American Society for Dermatologic Surgery (ASDS)
• American College of Phlebology
• European Society for Vascular Surgery (ESVS)
• Indian Medical Association (IMA)

Public Domain Sources:

• National Health Service (NHS)
• Centers for Disease Control and Prevention (CDC)

Proprietary Elements:

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years